Yeast Strain Engineering for Human-Like O-Glycosylation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Therapeutic proteins produced in yeast systems often provoke an immunogenic response in humans due to structural differences in O-glycosylation pathways, leading to reduced effectiveness and potential adverse effects upon repeated administration.
Innovation Solution
Engineering lower eukaryotic host cells, such as yeast, to produce glycoproteins with human-like O-glycosylation patterns by knocking out endogenous O-glycosylation genes and expressing human O-linked glycosylation enzymes, resulting in recombinant glycoproteins with improved immunogenicity and pharmacokinetic properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If yeast systems are used to produce therapeutic proteins, then production efficiency and cost-effectiveness are improved, but immunogenicity increases due to fungal O-glycosylation patterns
Solution Approach 1:
The patent applies parameter changes by modifying the glycosylation parameters of the yeast system. Specifically, it alters the O-glycosylation pattern from fungal type (with alpha-1,3-linked mannose residues) to human-like type (with beta-1,4-linked galactose and sialic acid residues) by introducing human glycosyltransferase genes (beta-1,4-galactosyltransferase and alpha-2,6-sialyltransferase) into the yeast expression system. This parameter change resolves the contradiction by maintaining high productivity while eliminating immunogenicity.
2Object-affected harmful factors
If fungal O-glycosylation is reduced or eliminated, then immunogenicity is reduced, but structural differences between lower eukaryotes and mammals persist
Solution Approach 1:
The patent uses an intermediary approach by introducing human glycosyltransferase enzymes as mediators into the yeast system. These enzymes (beta-1,4-galactosyltransferase and alpha-2,6-sialyltransferase) act as intermediaries that bridge the gap between fungal and human glycosylation pathways, enabling the yeast to produce human-like O-glycosylated proteins while maintaining the ease of fungal expression systems.
Solution Approach 2:
The patent creates a composite glycosylation system by combining fungal yeast expression machinery with human glycosyltransferase enzymes. This composite approach allows the system to maintain the productive capabilities of yeast while acquiring human-like glycosylation capabilities, resolving the adaptability issue.
3Duration of action of moving object
If human-like O-glycosylation is introduced into yeast, then bioavailability and serum half-life are improved, but system complexity increases
Solution Approach 1:
The patent applies preliminary action by pre-introducing and expressing human glycosyltransferase genes in the yeast system before producing the therapeutic protein. This preliminary establishment of human-like glycosylation capability ensures that when the therapeutic protein is produced, it automatically receives the correct human-like O-glycosylation, improving serum half-life without requiring post-production modifications.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach significantly reduces immunogenicity and enhances bioactivity of therapeutic proteins by mimicking human O-glycosylation, leading to improved bioavailability and serum half-life, facilitating better in vivo drug activity.
Implementation Method 1
the disclosure is concerned with lower eukaryotic cells, such as yeast strains, genetically engineered to produce glycoproteins having humanized O-glycosylation
Implementation Method 2
expressing human O-linked glycosylation enzymes, resulting in recombinant glycoproteins with improved immunogenicity and pharmacokinetic properties
Data Source
Figure 1
Figure 2A~2B
Figure 3A~3B
AI summary
Lower eukaryotic host cells have been recombinantly engineered to produce glycoprotein having human-like O-glycosylation. The glycoproteins are useful for the production of glycoprotein compositions with advantages for the production of human therapeutics.